日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ATMPs prepared under hospital exemption: European Blood Alliance position paper

根据医院豁免规定制备的ATMP:欧洲血液联盟立场文件

Domanović, Dragoslav; Turner, Marc; Jungbauer, Christof; Rodrigues, Bernardo; Nystedt, Johanna; Rožman, Primož; Debattista, Monique; Wang, Tengyu; Kristoffersen, Einar Klæboe; Perera, Kalinga; Švajger, Urban; Hook, Lilian; Jacques, Marjolaine; Sousa, Ana Paula; Hansen, Marten; O'Leary, Peter; Tiberghien, Pierre

Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease

中和 I 型干扰素的自体抗体可治疗重症波瓦桑病毒病、乌苏图病毒病或罗斯河病毒病患者

Adrian Gervais, Paul Bastard, Lucy Bizien, Céline Delifer, Pierre Tiberghien, Chaturaka Rodrigo, Francesca Trespidi, Micol Angelini, Giada Rossini, Tiziana Lazzarotto, Francesca Conti, Irene Cassaniti, Fausto Baldanti, Francesca Rovida, Alessandro Ferrari, Davide Mileto, Alessandro Mancon, Laurent A

Timing is essential: Humoral and cellular responses to SARS-CoV-2 vaccination in a cohort of patients with auto-immune diseases treated with rituximab

时机至关重要:接受利妥昔单抗治疗的一组自身免疫性疾病患者对 SARS-CoV-2 疫苗接种的体液和细胞反应

Irène Gallais Sérézal, Laurie Spehner, Marie Kroemer, Inès Bourezane, Nadine Meaux-Ruault, Clément Prati, Andréa Pastissier, Juliette Lodovichetti, Pierre Tiberghien, François Aubin

Transfused Red Blood Cell Characteristics and Kidney Transplant Outcomes Among Patients Receiving Early Posttransplant Transfusion

输注红细胞特征与肾移植早期输血患者的肾移植预后

Gaiffe, Emilie; Vernerey, Dewi; Bardiaux, Laurent; Leroux, Franck; Meurisse, Aurelia; Bamoulid, Jamal; Courivaud, Cecile; Saas, Philippe; Hazzan, Marc; Tiberghien, Pierre; Ducloux, Didier

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

COVID-19康复期血浆队列研究中炎症标志物和I型干扰素自身抗体

Fabrice Cognasse,Hind Hamzeh-Cognasse,Mickael Rosa,Delphine Corseaux,Brigitte Bonneaudeau,Chloe Pierre,Julie Huet,Charles Antoine Arthaud,Marie Ange Eyraud,Amélie Prier,Anne Claire Duchez,Theo Ebermeyer,Marco Heestermans,Estelle Audoux-Caire,Quentin Philippot,Tom Le Voyer,Olivier Hequet,Anne-Marie Fillet,Patricia Chavarin,Dominique Legrand,Pascale Richard,France Pirenne,Pierre Gallian,Jean Laurent Casanova,Sophie Susen,Pascal Morel,Karine Lacombe,Paul Bastard,Pierre Tiberghien

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.

康复血浆治疗 COVID 的炎症特征:阿莫托沙林/UVA 病原体减少技术的影响

Cognasse Fabrice, Hamzeh-Cognasse Hind, Duchez Anne-Claire, Shurko Natalia, Eyraud Marie-Ange, Arthaud Charles-Antoine, Prier Amélie, Heestermans Marco, Hequet Olivier, Bonneaudeau Brigitte, Rochette-Eribon Sandrine, Teyssier Françoise, Barlet-Excoffier Valérie, Chavarin Patricia, Legrand Dominique, Richard Pascale, Morel Pascal, Mooney Nuala, Tiberghien Pierre

Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis

解码新冠病毒mRNA疫苗诱发心肌炎的人类遗传和免疫学基础

Bolze, Alexandre; Mogensen, Trine H; Zhang, Shen-Ying; Abel, Laurent; Andreakos, Evangelos; Arkin, Lisa M; Borghesi, Alessandro; Brodin, Petter; Hagin, David; Novelli, Giuseppe; Okada, Satoshi; Peter, Jonny; Renia, Laurent; Severe, Karine; Tiberghien, Pierre; Vinh, Donald C; Cirulli, Elizabeth T; Casanova, Jean-Laurent; Hsieh, Elena W Y

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors

抗 SARS-CoV-2 T 细胞反应的质量可预测恢复期血浆捐献者的中和抗体滴度

Marie Kroemer, Laura Boullerot, Mélanie Ramseyer, Laurie Spehner, Christophe Barisien, Eleonore Gravelin, Adeline Renaudin, Fabrice Cognasse, Pierre Gallian, Olivier Hermine, Karine Lacombe, Pierre Tiberghien, Olivier Adotévi4

Non-invasive continuous cardiac output monitoring in thoracic cancer surgery: A comparative study between calibrated pulse contour analysis and chest bioreactance

胸部肿瘤手术中无创连续心输出量监测:校准脉搏轮廓分析与胸部生物阻抗的比较研究

Fellahi, Jean-Luc; Abraham, Paul; Tiberghien, Nicolas; Coelembier, Clément; Maury, Jean-Michel; Bendjelid, Karim

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Bamlanivimab + etesevimab 疗法可诱导 COVID-19 合并 B 细胞恶性肿瘤患者出现 SARS-CoV-2 免疫逃逸突变和继发性临床恶化。

Pommeret, F; Colomba, J; Bigenwald, C; Laparra, A; Bockel, S; Bayle, A; Michot, J-M; Hueso, T; Albiges, L; Tiberghien, P; Marot, S; Jary, A; Lacombe, K; Barlesi, F; Griscelli, F; Colomba, E